(Q38065210)

28 August 2017

1 reference

title

Elobixibat for the treatment of constipation (English)

1 reference

28 August 2017

2

Michael Camilleri

1 reference

28 August 2017

Banny S Wong

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

8 December 2012

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

published in

1 reference

28 August 2017

volume

22

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

277-284

1 reference

Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Epidemiology of constipation in North America: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Chronic constipation: overview and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Chronic constipation: a survey of the patient perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Two randomized trials of linaclotide for chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Scintigraphic biomarkers for colonic dysmotility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Association between fecal bile acids and colorectal cancer: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Fecal steroids and urinary volatile phenols in four Scandinavian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.753056

10.1517/13543784.2013.753056

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference